GlassScriptPhysician profile
Derek W Thigpin
NPI 1265691380
$2,613.80
in general payments reported to CMS, 2019-2025
18 companies · $791 in 2025
The $791 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $88.22 · 2022: $203 · 2023: $417 · 2024: $558 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690 · Education: $75.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.23 |
| Education | $75.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $877.66 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $398.92 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $258.28 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Gilead Sciences, INC. | $257.01 | 2024-2025 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $240.23 | 2024-2025 | Tremfya, Stelara |
| Pfizer INC. | $200.38 | 2019-2025 | |
| Madrigal Pharmaceuticals | $83.88 | 2025 | Rezdiffra |
| Genzyme Corporation | $53.60 | 2025 | |
| Ucb, INC. | $43.04 | 2019 | |
| Aimmune Therapeutics, INC. | $41.35 | 2025 | Vowst, Zenpep |
| Regeneron Healthcare Solutions, INC. | $37.68 | 2024-2025 | Dupixent |
| Alexion Pharmaceuticals, INC. | $20.59 | 2019 | |
| Janssen Scientific Affairs, LLC | $20.40 | 2025 | Tremfya |
| Ardelyx, INC. | $19.97 | 2025 | Ibsrela |
| Celgene Corporation | $19.26 | 2024 | Zeposia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.36 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.88 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Thigpin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.